Skye Bioscience, Inc. (SKYE)
2.17
-0.07
(-3.12%)
USD |
NASDAQ |
Aug 24, 16:00
2.12
-0.05
(-2.30%)
Pre-Market: 09:27
Skye Bioscience Enterprise Value : -0.3526M for Aug. 24, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| August 24, 2026 | -0.3526M |
| August 21, 2026 | -0.0451M |
| August 20, 2026 | -0.031M |
| August 19, 2026 | 0.8651M |
| August 18, 2026 | 2.731M |
| August 17, 2026 | 4.703M |
| August 14, 2026 | 7.739M |
| August 13, 2026 | 9.128M |
| August 12, 2026 | 9.405M |
| August 11, 2026 | 9.124M |
| August 10, 2026 | 8.829M |
| August 07, 2026 | 8.368M |
| August 06, 2026 | 6.692M |
| August 05, 2026 | 9.855M |
| August 04, 2026 | 10.32M |
| August 03, 2026 | 10.65M |
| July 31, 2026 | 10.09M |
| July 30, 2026 | 10.51M |
| July 29, 2026 | 11.73M |
| July 28, 2026 | 11.72M |
| July 27, 2026 | 12.00M |
| July 24, 2026 | 13.02M |
| July 23, 2026 | 13.84M |
| July 22, 2026 | 12.61M |
| July 21, 2026 | 12.61M |
| Date | Value |
|---|---|
| July 20, 2026 | 13.09M |
| July 17, 2026 | 12.93M |
| July 16, 2026 | 12.21M |
| July 15, 2026 | 11.42M |
| July 14, 2026 | 11.91M |
| July 13, 2026 | 13.38M |
| July 10, 2026 | 14.36M |
| July 09, 2026 | 14.75M |
| July 08, 2026 | 14.82M |
| July 07, 2026 | 14.83M |
| July 06, 2026 | 14.83M |
| July 02, 2026 | 14.73M |
| July 01, 2026 | 13.84M |
| June 30, 2026 | 14.48M |
| June 29, 2026 | 6.756M |
| June 26, 2026 | 7.086M |
| June 25, 2026 | 8.087M |
| June 24, 2026 | 7.054M |
| June 23, 2026 | 7.792M |
| June 22, 2026 | 8.101M |
| June 18, 2026 | 8.048M |
| June 17, 2026 | 8.196M |
| June 16, 2026 | 8.438M |
| June 15, 2026 | 8.828M |
| June 12, 2026 | 10.85M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Regeneron Pharmaceuticals, Inc. | 80.37B |
| Viking Therapeutics, Inc. | 3.379B |
| ACADIA Pharmaceuticals, Inc. | 4.221B |
| Alnylam Pharmaceuticals, Inc. | 31.24B |
| Savara, Inc. | 999.39M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -10.79M |
| Total Expenses (Quarterly) | 10.79M |
| EPS Diluted (Quarterly) | -2.174 |
| Earnings Yield | -469.1% |
| Normalized Earnings Yield | -448.02 |